EA202091533A1 - Способы лечения диабета, гепатита и/или воспалительного заболевания печени - Google Patents

Способы лечения диабета, гепатита и/или воспалительного заболевания печени

Info

Publication number
EA202091533A1
EA202091533A1 EA202091533A EA202091533A EA202091533A1 EA 202091533 A1 EA202091533 A1 EA 202091533A1 EA 202091533 A EA202091533 A EA 202091533A EA 202091533 A EA202091533 A EA 202091533A EA 202091533 A1 EA202091533 A1 EA 202091533A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
hepatitis
treatment
liver disease
methods
Prior art date
Application number
EA202091533A
Other languages
English (en)
Inventor
Майкл А. Лайнс
Юй-Хуа Цзэн
Мэттью Д. Лайнс
Original Assignee
Юниверсити Оф Коннектикут
Джослин Диабетс Сентр, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Коннектикут, Джослин Диабетс Сентр, Инк. filed Critical Юниверсити Оф Коннектикут
Publication of EA202091533A1 publication Critical patent/EA202091533A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем документе раскрыты применения ингибитора внеклеточного металлотионеина (МТ) человека для лечения расстройства, выбранного из группы, состоящей из диабета, предиабета, нарушения толерантности к глюкозе, гепатита и/или воспалительного заболевания печени, и композиций, содержащих внеклеточный МТ человека.
EA202091533A 2018-01-17 2019-01-17 Способы лечения диабета, гепатита и/или воспалительного заболевания печени EA202091533A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862618332P 2018-01-17 2018-01-17
PCT/US2019/013934 WO2019143767A1 (en) 2018-01-17 2019-01-17 Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Publications (1)

Publication Number Publication Date
EA202091533A1 true EA202091533A1 (ru) 2020-11-16

Family

ID=65324621

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091533A EA202091533A1 (ru) 2018-01-17 2019-01-17 Способы лечения диабета, гепатита и/или воспалительного заболевания печени

Country Status (14)

Country Link
US (3) US11866488B2 (ru)
EP (1) EP3740282A1 (ru)
JP (2) JP7486423B2 (ru)
KR (1) KR20200110659A (ru)
CN (1) CN111801140A (ru)
AU (2) AU2019209491B2 (ru)
BR (1) BR112020014346A2 (ru)
CA (1) CA3088661A1 (ru)
EA (1) EA202091533A1 (ru)
IL (1) IL276097A (ru)
MX (1) MX2020007384A (ru)
PH (1) PH12020551076A1 (ru)
SG (1) SG11202006421RA (ru)
WO (1) WO2019143767A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3144014A1 (en) 2019-07-15 2021-01-21 Michael LYNES Metallothionein antibodies and their use
CN110551726B (zh) * 2019-09-06 2021-04-09 上海市肺科医院 一种结核杆菌阿拉伯半乳聚糖适配子及其应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR102191405B1 (ko) * 2020-09-15 2020-12-16 주식회사 에이스바이오메드 간 질환 예방 또는 치료용 조성물
CN115317502B (zh) * 2021-12-21 2023-07-07 青岛市市立医院 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030007973A1 (en) * 2001-06-22 2003-01-09 Lynes Michael A. Methods and compositions for manipulation of the immune response using anti-metallothionein antibody
CA2658673A1 (en) 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
WO2011050052A2 (en) * 2009-10-20 2011-04-28 Georgia State University Research Foundation, Inc. Protein agent for diabetes treatment and beta cell imaging
BR112013007850A2 (pt) 2010-10-14 2016-06-07 Immunahr Ab 1,2-diidro-4-hidróxi-2-oxo-quinolina-3-carboxanilidas como ativadores de ahr
WO2013007678A1 (en) 2011-07-08 2013-01-17 Universiteit Gent Use of antagonists targeting metallothionein to treat intestinal inflammation
US20160215042A1 (en) * 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
DK3149049T3 (da) * 2014-05-27 2023-01-23 Univ Queensland Il-22 til anvendelse til behandling af stofskiftesygdomme
JP2017523790A (ja) 2014-08-07 2017-08-24 レグルス セラピューティクス インコーポレイテッド 代謝障害のためのマイクロｒｎａの標的化

Also Published As

Publication number Publication date
AU2019209491A1 (en) 2020-07-23
KR20200110659A (ko) 2020-09-24
PH12020551076A1 (en) 2021-08-16
JP2024028454A (ja) 2024-03-04
BR112020014346A2 (pt) 2020-12-08
US11866488B2 (en) 2024-01-09
SG11202006421RA (en) 2020-08-28
AU2022215285A1 (en) 2022-09-29
US20200369757A1 (en) 2020-11-26
US20240067710A1 (en) 2024-02-29
AU2022215285B2 (en) 2024-08-29
US20240025981A1 (en) 2024-01-25
JP2021511296A (ja) 2021-05-06
MX2020007384A (es) 2020-10-19
WO2019143767A1 (en) 2019-07-25
JP7486423B2 (ja) 2024-05-17
IL276097A (en) 2020-08-31
EP3740282A1 (en) 2020-11-25
AU2019209491B2 (en) 2022-05-19
CA3088661A1 (en) 2019-07-25
CN111801140A (zh) 2020-10-20

Similar Documents

Publication Publication Date Title
EA202091533A1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
MX2020008271A (es) Inhibidor de fap.
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
CY1124300T1 (el) Μεθοδοι για τη χρηση αγωνιστων fxr
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA201792562A1 (ru) Глюкагон и коагонисты гпп-1
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
EA200900959A1 (ru) Ингибиторы мек
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
EA202190059A1 (ru) Конъюгаты связующее-активное средство, направленные против cxcr5, имеющие ферментативно расщепляемые линкеры и улучшенный профиль активности
EA201992272A1 (ru) Ацилированное инсулиновое соединение
EA200901080A1 (ru) Новые нуклеозидные аналоги для лечения вирусных инфекций
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201171228A1 (ru) Производные хиназолиндиона, их получение и их различные терапевтические применения
DK1809270T3 (da) 5,6,7-trihydroxyheptansyre og analoger til behandling af okulære sygdomme og sygdomme associeret med hyperproliferative og angiogeniske reaktioner
EA202192488A1 (ru) Антитела против tsg-6 и их применения
DK3574912T3 (da) Sammensætning til behandling af diabetisk sygdom
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
CY1124851T1 (el) Νεες ενωσεις
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон